The core purpose of Regadenoson is generally used as a diagnostic agent in specialized cardiac imaging procedures, which supports the evaluation of heart function in clinical settings where physical exercise is inappropriate or insufficient.

This agent is commonly used as a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. This use is relevant across domains involving cardiovascular diagnostics, primarily to support the evaluation for Coronary Artery Disease (CAD).

Clinical Use and Patient Benefits

Regadenoson is applied across domains involving cardiovascular diagnostics where further investigation for CAD is needed, and in scenarios involving the patient's physical inability to exert due to mobility restrictions or other complex patient scenarios. The main benefit supports the process of risk stratification for the patient and assists in guiding subsequent management decisions. This capability may assist with maintaining functional stability, offering support for patients with physical limitations who require assessment of their heart’s blood flow.

Quick Fact: Support for Physical Limitations
Primary Utility	Is applied in addressing the clinical challenge of inability to exert adequately for a stress test.
Benefit Framing	Provides a well-tolerated, non-invasive option when physical exertion is not appropriate.

Regulatory References

1. FDA's prescribing information

Who Can and Cannot Use Regadenoson?

Eligibility for Regadenoson use is strictly defined by regulatory guidelines, focusing on pre-existing conditions and specific population groups. Regadenoson is approved for use in adult patients (18 years of age) who are unable to undergo adequate exercise stress during Radionuclide Myocardial Perfusion Imaging (MPI).

---

Contraindications and Prohibited Use

Regadenoson is contraindicated (must not be used) in patients with the following conditions, unless a functional pacemaker is present:

• Second- or third-degree atrioventricular (AV) block.
• Sick sinus syndrome (sinus node dysfunction).
• Known hypersensitivity to the active ingredient or formulation components.

---

Use in Specific Populations

Population Group	Regulatory Status
Pediatric Patients (< 18 years)	Not recommended; safety and effectiveness have not been established.
Pregnant Women	Not recommended unless the potential benefit justifies the risk to the fetus.
Lactating Women	Breastfeeding is not recommended for at least 10 hours after administration.
Renal/Hepatic Impairment	No dose adjustment is needed for patients with any degree of renal or hepatic impairment.

Use requires special caution in patients with a history of bronchoconstrictive lung disease (e.g., asthma, COPD) and those with risk factors for seizures or severe hypotension.

Interactions with other medicines and products

Official regulatory information outlines specific interaction concerns, primarily focusing on medicinal products and substances that may interfere with Regadenoson's intended pharmacological effect or significantly alter its exposure.

Pharmacodynamic and Inhibitory Interactions

Substances that act as adenosine receptor antagonists may interfere with the activity of Regadenoson. The official profile highlights the following required restrictions:

• Methylxanthines: This class, which includes Theophylline and non-medicinal products containing Caffeine, must be avoided for at least 12 hours prior to Regadenoson administration. These agents are non-specific adenosine receptor antagonists and may inhibit the intended vasodilating effect.
• Dipyridamole: This nucleoside transport inhibitor may potentiate the effects of Regadenoson. When possible, Dipyridamole should be withheld for at least two days prior to administration.

Pharmacokinetic Considerations

Based on in vitro studies, Regadenoson is not expected to significantly inhibit the metabolism of other medicinal products. It showed no inhibition of major Cytochrome P450 enzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, or 3A4), indicating a low likelihood of altering the pharmacokinetics of co-administered drugs metabolized by these systems.

Other Concurrently Administered Agents

In clinical studies, other cardioactive medicinal products, including beta-blockers, calcium channel blockers, ACE inhibitors, Angiotensin II Receptor Blockers, nitrates, and cardiac glycosides, were administered concurrently without apparent adverse effects on the overall safety profile.

Regadenoson is a highly selective agonist of the A2 A adenosine receptor . It demonstrates significantly greater affinity for the A2 A receptor compared to the A1 receptor, and negligible affinity for A2 B or A3 receptor subtypes. This selectivity restricts the mechanism to the A2 A pathway, bypassing other adenosine receptor-mediated effects.

Binding to the A2 A receptor initiates a G s-protein-coupled signaling cascade. Receptor activation increases intracellular levels of cyclic adenosine monophosphate ( cAMP), which drives the relaxation of smooth muscle cells localized in the coronary arterioles. This cellular modulation results in coronary vasodilation, a physiological change that elevates the rate of coronary flow reserve. The physiological half-life of the resulting vasodilation is approximately 2–3 minutes.

Instruction Map: How to use Regadenoson

Regadenoson is administered as a single, fixed-dose, intravenous (IV) injection in a controlled clinical setting. The use is strictly limited to a medical facility where appropriate cardiac monitoring and resuscitation equipment are immediately available.

---

Dosing and Administration Logistics

The recommended dosage is a single 5 mL (0.4 mg regadenoson) injection. This fixed dose is administered without the need for adjustment based on the patient’s body weight. Dosage adjustment is also not required for older adults or patients with renal or hepatic impairment.

---

Procedural and Timing Requirements

Proper use requires specific patient preparation. Patients are instructed to avoid consumption of any products containing methylxanthines (e.g., caffeine, theophylline) for at least 12 hours before the scheduled procedure. Additionally, dipyridamole should generally be withheld for a minimum of two days prior to administration.

Administration follows a strict time-sensitive protocol:

• The fixed 0.4 mg dose must be injected rapidly, over approximately 10 seconds, into a peripheral vein.
• This is followed immediately by a 5 mL saline flush.
• The radionuclide tracer for the myocardial perfusion imaging (MPI) is then administered 10 to 20 seconds after the saline flush.

The drug product itself must be visually inspected for particulate matter or discoloration prior to administration and should not be used if present.

Evidence for Use as a Pharmacologic Stress Agent in MPI

Regadenoson was studied for its profile as an agent in research exploring its role in increasing blood flow in the heart for diagnostic imaging, such as Myocardial Perfusion Imaging (MPI). The primary research approach involved large, multicenter, randomized clinical trials that compared the use of Regadenoson to an established agent (Adenosine). These trials monitored outcomes related to physiological strain and coronary hyperemia, with findings describing patterns observed in the measured blood flow and the subsequent diagnostic images. These initial studies contribute to the broader evidence landscape by characterizing the use of Regadenoson in populations referred for heart evaluation.

---

Studies Comparing Regadenoson to Established Pharmacologic Stress Agents

Comparative research was evaluated in patients to explore how the diagnostic information gathered using Regadenoson aligned with the information gathered using the older agent, Adenosine. Studies monitored the physiological response, including changes in heart rate and blood pressure, and the resulting images used for diagnosis. Research described patterns related to physical discomfort and systemic imbalance experienced during the procedure, comparing these between the two agents to assess diagnostic agreement.

---

Research in Special Patient Populations and Co-morbidities

Initial studies focused on a general adult population, leading researchers to explore its use in specific patient groups. Studies have been conducted on patients with co-morbidities, such as those with Chronic Kidney Disease (CKD) or End-Stage Renal Disease (ESRD), where outcomes reflecting daily functioning were monitored. Research describes patterns observed in these specialized populations, contributing to understanding the profile of Regadenoson across diverse cohorts.

---

Areas of Uncertainty and Research Gaps

Evidence is limited in certain areas. Follow-up durations were limited in the initial comparative trials, meaning that long-term effects are not fully established, and there is limited information for long-term outcomes. Data remain limited for high-risk patient groups, such as those with severe heart rhythm or conduction abnormalities, as these individuals were typically excluded from the initial trials. Results apply only to the populations studied.

Common questions about Regadenoson (FAQ)

Q: What is the main purpose of Regadenoson?

According to the official product information, Regadenoson is a medication used as a pharmacologic stress agent. This means it is given to simulate the effects of exercise on the heart when a patient is unable to exercise adequately. It is used in a specific type of test called myocardial perfusion imaging (MPI) to assist in the assessment of blood flow to the heart muscle.

Q: Is Regadenoson given as a pill or an injection?

Official product information states that Regadenoson is administered as a rapid intravenous (IV) injection. It is administered by a healthcare professional directly into a vein. It is not available as an oral pill or liquid.

Q: How long does it take for Regadenoson to work?

Studies and official information indicate that the key effects of Regadenoson, such as changes in heart rate and blood pressure, occur very quickly. Peak effects are generally observed within 1 to 4 minutes following injection. This rapid onset is relevant to its use during specific imaging tests.

Q: Can I have caffeine before receiving Regadenoson?

Regulatory documents state that it is important to avoid consuming caffeine-containing products before receiving Regadenoson. Official guidance recommends avoiding all sources of caffeine for at least 12 hours before the administration of the drug. This includes coffee, tea, chocolate, and certain other beverages or foods.

Q: Will Regadenoson make my heart race?

According to official product information, temporary changes in heart rate and rhythm are possible during the use of this medication. This occurs because the drug increases blood flow to the heart muscle, and these temporary changes are often expected as part of the stress simulation process. These vital signs are closely monitored by the medical team throughout the procedure.

Q: How does Regadenoson help in stress testing?

Regadenoson is utilized in stress testing because it acts as a vasodilator. Regulatory documents explain that it temporarily widens the coronary arteries, which are the blood vessels supplying the heart muscle. This action mimics the increased blood flow to the heart that normally happens during physical exercise.

Q: Is it called "Lexiscan" or "Regadenoson"?

The name Regadenoson refers to the active drug ingredient, also known as the generic name. Lexiscan is the brand name under which the medication is often marketed and used. Both names refer to the same medication used for myocardial perfusion imaging.

Storage and Disposal of Regadenoson

Regadenoson injection must be stored strictly according to official regulatory requirements to maintain its integrity.

---

Storage Conditions

• Required Temperature: Store at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). Excursions are permitted up to 30 C.
• Freezing Prohibition: The product must be protected from freezing at all times.
• Inspection: The solution must be visually inspected prior to use. It should be a clear, colorless liquid, and must not be administered if particulate matter or discoloration is present.
• Child Safety: The product must be kept out of the reach and sight of children.

---

Disposal Instructions

Unused product and associated waste materials, including the container, must be disposed of in accordance with local, regional, national, and international regulations for pharmaceutical waste.